|  Help  |  About  |  Contact Us

Publication : β1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations.

First Author  McCurdy S Year  2022
Journal  FASEB J Volume  36
Issue  12 Pages  e22629
PubMed ID  36349990 Mgi Jnum  J:333194
Mgi Id  MGI:7434824 Doi  10.1096/fj.202200907RR
Citation  McCurdy S, et al. (2022) beta1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J 36(12):e22629
abstractText  beta1 integrins are important in blood vessel formation and function, finely tuning the adhesion of endothelial cells to each other and to the extracellular matrix. The role of integrins in the vascular disease, cerebral cavernous malformation (CCM) has yet to be explored in vivo. Endothelial loss of the gene KRIT1 leads to brain microvascular defects, resulting in debilitating and often fatal consequences. We tested administration of a monoclonal antibody that enforces the active beta1 integrin conformation, (clone 9EG7), on a murine neonatal CCM mouse model, Krit1(flox/flox) ;Pdgfb-iCreERT2 (Krit1(ECKO) ), and on KRIT1-silenced human umbilical vein endothelial cells (HUVECs). In addition, endothelial deletion of the master regulator of integrin activation, Talin 1 (Tln1), in Krit1(ECKO) mice was performed to assess the effect of completely blocking endothelial integrin activation on CCM. Treatment with 9EG7 reduced lesion burden in the Krit1(ECKO) model and was accompanied by a strong reduction in the phosphorylation of the ROCK substrate, myosin light chain (pMLC), in both retina and brain endothelial cells. Treatment of KRIT1-silenced HUVECs with 9EG7 in vitro stabilized cell-cell junctions. Overnight treatment of HUVECs with 9EG7 resulted in significantly reduced total surface expression of beta1 integrin, which was associated with reduced pMLC levels, supporting our in vivo findings. Genetic blockade of integrin activation by Tln1(ECKO) enhanced bleeding and did not reduce CCM lesion burden in Krit1(ECKO) mice. In sum, targeting beta1 integrin with an activated-specific antibody reduces acute murine CCM lesion development, which we found to be associated with suppression of endothelial ROCK activity.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

6 Bio Entities

Trail: Publication

0 Expression